1. Home
  2. THE CING
  3. Clinical Sciences
  4. Haematology Services
  5. Staff
  6. Panayiota Papasavva
Back to Staff List
Panayiota Papasavva

Haematologist

MD, MSc, PhD

Download CV

Current Position

Haematologist
Member of ERN-EuroBloodNet

 

Education

  • Sept 2021, PhD in Medical Genetics, CING, CyprusTitle: “Genome-editing-mediated lineage-specific knockdown of disease modifiers as therapy of β- haemoglobinopathies”
  • Sep 2017, MSc in Medical Genetics awarded with Distinction, CING, Cyprus
  • Nov 2013, Title of medical specialty in Haematology, Public health department, Attica domain, Greece
  • June 2000, Medical Degree, Grade “Excellent”, Medical School of Athens, National and Kapodistrian University of Athens, Greece

Biography

Dr Panayiota Papasavva MD, MSc, PhD, completed her medical studies at the National and Kapodistrian University of Athens in 2000 and her haematology residency at the Haematology Clinic of the General Hospital of Athens "G. Gennimatas” and the Haematology Unit of the Third University Clinic of “Sotiria” Hospital in 2013. She is currently working in the outpatient clinical care at the Cyprus Institute of Neurology and Genetics, specialising in the diagnosis and management of genetic haematological conditions, such as rare red blood cell defects, bone marrow failure syndromes, immune disorders, rare bleeding-coagulation disorders, disorders of iron metabolism and haem synthesis, syndromes with genetic predisposition to rare blood disorders. She is also conducting research in the field of gene therapy/genome editing of haemoglobinopathies and other rare anaemias and has extensive knowledge and skill in primary HSPC culture, CRISPR/Cas and base editor design, LV design and production, transcriptomics, and genomics analyses in haematopoietic cells, with particular focus on applications in disorders of erythropoiesis. Panayiota is an active member of ERN-EuroBloodNet, the European Hematology Association, the Cyprus Society of Haematology, the Hellenic Society of Haematology, the Cyprus Society of Human Genetics and the Hellenic Society of Gene Therapy and Regenerative Medicine.

Panayiota Papasavva has authored 12 peer-reviewed articles and has an h index of 7 (i10 index 6). 
 

Publications:

  1. High-efficiency editing in hematopoietic stem cells and the HUDEP-2 cell line based on in vitro mRNA synthesis. Nikoletta Papaioannou, Petros Patsali, Basma Naiisseh, Panayiota L Papasavva, Lola Koniali, Ryo Kurita, Yukio Nakamura, Soteroula Christou, Maria Sitarou, Claudio Mussolino, Toni Cathomen, Marina Kleanthous and Carsten Werner Lederer*, Front Genome Ed. 2023 Mar 8;5:1141618. doi: 10.3389/fgeed.2023.1141618. eCollection 2023.
  2. Catching Them Early: Framework Parameters and Progress for Prenatal and Childhood Application of Advanced Therapies Carsten W. Lederer, Lola Koniali, Tina Buerki-Thurnherr, Panayiota L. Papasavva, Stefania La Grutta, Amelia Licari, Frantisek Staud, Donato Bonifazi, and Marina Kleanthous. Pharmaceutics. 2022;14(4):793. https://doi.org/10.3390/pharmaceutics14040793
  3. CRISPR Editing Enables Consequential Tag-Activated MicroRNA-Mediated Endogene Deactivation. Panayiota L. Papasavva, Petros Patsali , Constantinos C. Loucari, Ryo Kurita, Yukio Nakamura, Marina Kleanthous, Carsten W. Lederer. Int J Mol Sci. 2022, 23(3):1082. https://doi.org/10.3390/ijms23031082
  4. Distinct miRNA Signatures and Networks Discern Fetal from Adult Erythroid Differentiation and Primary from Immortalized Erythroid CellsPanayiota L. Papasavva, Nikoletta Y. Papaioannou, Petros Patsali, Ryo Kurita, Yukio Nakamura, Maria Sitarou, Soteroulla Christou, Marina Kleanthous, and Carsten W. Lederer. Int. J. Mol. Sci. 2021, 22(7):3626, https://doi.org/10.3390/ijms22073626
  5. Relative and absolute quantification of aberrant and normal splice variants in HBBIVSI- 110(G>A) β-thalassemiaPetros Patsali, Panayiota Papasavva, Soteroulla Christou, Maria Sitarou, Michael N. Antoniou, Carsten W. Lederer *, Marina Kleanthous Int. J. Mol. Sci. 2020, 21(18), 6671; doi: 10.3390/ijms21186671
  6. Genetic Modifiers at the Crossroads of Personalised Medicine for Haemoglobinopathies. Coralea Stephanou, Stella Tamana, Anna Minaidou, Panayiota Papasavva, Marina Kleanthous and Petros Kountouris. J. Clin. Med. 2019, 8(11), 1927; https://doi.org/10.3390/jcm8111927
  7. Gene Therapy Getting Personal: Mutation-Specific Editing and Gene Addition Strategies for β- ThalassaemiaCarsten W. Lederer, Petros Patsali, Panayiota Papasavva, Coralea Stephanou, Giandomenico Turchiano, Petros Ladas, Argyro Floga, Soteroulla Christou, Maria Sitarou, Annita Kolagnou, Claudio Mussolino, Tatjana I. Cornu, Michael N. Antoniou, Toni Cathomen, Marina Kleanthous Hemoglobin, 2019, 43(6):330-330, https://doi.org/10.1080/03630269.2020.1719599
  8. Correction of IVS I-110(G>A) beta-thalassemia by CRISPR/Cas- and TALEN-mediated disruption of aberrant regulatory elements in human hematopoietic stem and progenitor cellsPetros Patsali, Giandomenico Turchiano, Panayiota Papasavva, Marianna Romito, Constantinos C. Loucari, Coralea Stephanou, Soteroulla Christou, Maria Sitarou, Claudio Mussolino, Tatjana I. Cornu, Michael N. Antoniou, Carsten W. Lederer, Toni Cathomen, Marina Kleanthous. Haematologica 2019 April. doi:10.3324/haematol.2018.215178 (2019)
  9. Rare opportunities: CRISPR/Cas9-based therapy development for rare genetic diseases. Papasavva P, Kleanthous M, Lederer CW. Mol. Diagnosis Ther. 23, 201–222 (2019); https://doi.org/10.1007/s40291-019-00392-3
  10. Short-hairpin RNA against aberrant HBBIVSI-110(G>A) mRNA restores β-globin levels in a novel cell model and acts as mono- and combination therapy for β-thalassemia in primary hematopoietic stem cellsPatsali P, Papasavva P, Stephanou C, Christou S, Sitarou M, Antoniou M, Lederer CW, Kleanthous M. Haematologica 2018 Apr 26. doi: 10.3324/haematol.2018.189357. PMID: 29700171
  11. Rapid and sensitive assessment of globin chains for gene and cell therapy of haemoglobinopathiesLoucari CC, Patsali P, van Dijk TB, Stephanou C, Papasavva P, Zanti M, Kurita R, Nakamura Y, Christou S, Sitarou M, Philipsen S, Lederer CW, Kleanthous M. Hum Gene Ther Methods. 2018 Jan 12. doi: 10.1089/hgtb.2017.190
  12. Suitability of Small Diagnostic Peripheral-blood Samples for Cell-therapy Studies. Stephanou C, Papasavva P, Zachariou M, Patsali P, Epitropou M, Ladas P, Al-Abdulla R, Christou S, Antoniou MN, Lederer CW, Kleanthous M. Cytotherapy. 2017 Feb;19(2):311-326. doi: 10.1016/j.jcyt.2016.11.007. PMID: 28088294
     
winner